Oddo BHF - BENEVOLENTAI (BAI) BenevolentAI : Résultats S1 2024 sans surprise. Out-licencing de BEN-8744 en ligne de mire

Report

Oddo BHF

Damien Choplain ...

Oussema Denguir

BenevolentAI : Résultats S1 2024 sans surprise. Out-licencing de BEN-8744 en ligne de mire

>Un plan de réduction des dépenses qui porte ses fruits - BenevolentAI a communiqué hier ses résultats du S1 24. Nous en soulignons les points suivants : 1/ des revenus en baisse de 46% à 2.8 M£ provenant de la collaboration avec AstraZeneca et incluant les encaissements issus de la récente collaboration avec Merck qui devraient progresser sur la période S2 2024 -2026, 2/ une diminution des dépenses R&D de 39% à 19.5 M£ et 3/ une réduction des dépenses SG&A de 21% à 1...

20/09/2024 1 FR

Underlying

BENEVOLENTAI

See profile

LU2355630455 Euronext Amsterdam Luxembourg

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Damien Choplain

Oussema Denguir

Other Reports on these Companies

Oddo BHF

ODDO BHF Sma ll & MIDCAP MORNING NEWS - 20/09/2024

...

1h / 24m 1h / 24m 1 FR

Oddo BHF

ODDO BHF Small & MIDCAP MORNING NEWS - 09/20/2024

Tubacex is a solutions provider for the energy and mobility sectors through high value-added products (seamless stainless-steel tubes) and services. It has recently completed a successful transformation which should result in a much more stable results and cash flow profile going forward (EBITDA margin c.15% vs 10-year historical average of 9%) although 2024 will be a transition year ahead of the completion of the ADNOC contract and the closing of Mubadala’s transaction (acquisition o...

1h / 24m 1h / 24m 1 EN

Oddo BHF

BenevolentAI : H1 2024 results contained no surprises. Out-licensing of BEN-8744 in the spotlight

>Cost-cutting plan paying off - BenevolentAI released its H1 2024 results yesterday. Our key takeaways are as follows: 1/ revenues down 46% to £ 2.8m, marked both by lower revenues from the AstraZeneca collaboration and including receipts from the recent Merck collaboration, which are expected to grow over the H2 2024-2026 period, 2/ a 39% reduction in R&D expenditure to -£ 19.5m and 3/ a reduction in SG&A expenditure of 21% to -£ 10.3m, in line with the cost-cutting ...

1h / 42m 1h / 42m 1 EN

Oddo’s 2 Weeks Ahead_Friday 20 September 2024

...

1h 1h 1 EN

Matthias Desmarais

Matthias Desmarais

Oddo’s 2 Weeks Ahead_Vendredi 20 Septembre 2024

...

1h / 18m 1h / 18m 1 FR

Anthony Dick ... (+3)

Anthony Dick
Marc Lavaud
Michael Foundoukidis

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 20/09/2024

...

1h / 24m 1h / 24m 1 FR

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BenevolentAI : Résultats S1 2024 sans surprise. Out-licencing de BEN-8744 en ligne de mire

ODDO BHF Sma ll & MIDCAP MORNING NEWS - 20/09/2024

ODDO BHF Small & MIDCAP MORNING NEWS - 09/20/2024

BenevolentAI : H1 2024 results contained no surprises. Out-licensing of BEN-8744 in the spotlight

Oddo’s 2 Weeks Ahead_Friday 20 September 2024

Oddo’s 2 Weeks Ahead_Vendredi 20 Septembre 2024

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 20/09/2024

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe